FOR IMMEDIATE RELEASE  SK pharmteco Launches New Lentiviral Vector Analytical Services with Dedicated 20,000 sq. ft. Facility  King of Prussia, PA (May 21, 2024)—SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving the pharmaceutical and cell & gene therapy industry, today announced the upcoming launch of Lentiviral Vector (LVV) Analytical Services, a comprehensive suite of analytical testing solutions specifically designed for LVV and cell therapy programs. Coinciding with the launch is the commissioning of a new, state-of-the-art 20,000-square-foot CGMP testing facility, located on SK pharmteco’s King of Prussia campus, with dedicated laboratory space specifically designed for replication-competent lentivirus (RCL) testing and molecular based analytics.  The full platform is available for R&D testing now, with full CGMP testing capabilities in July 2024.  “The cell and gene therapy industry is experiencing tremendous growth, and the demand for robust analytical testing is critical to ensure patient safety and program success,” said Dana Cipriano, Global Head of Analytical Services for SK pharmteco. “These new services, combined with our dedicated lab space, allow clients unparalleled access to SK pharmteco’s robust testing platform assays and scientific expertise, with the capacity and capabilities to eliminate backlogs and expedite development timelines. We are committed to our clients, and having this platform demonstrates that commitment.”  Key Features of SK pharmteco’s LVV Analytical Services include:  Commitment to Patient Safety and Client Success  The launch of LVV Analytical Services builds on SK pharmteco’s capabilities to fully support, cell and gene therapy manufacturing. This strategic move strengthens SK pharmteco’s ability to offer a complete

Designed to shorten turnaround on manufacturing AAVs, this new platform offers Cell and Gene Therapy developers more flexibility in producing viral vectors for clinical and commercial use

SK Pharmteco Expands Capabilities with Majority Stake of Center for Breakthrough Medicines

CBM is the Exclusive CDMO Provider of an iCellis 500-based
Adeno-Associated Virus (AAV) Adherent Platform developed by the Gene Therapy Program at the University of Pennsylvania

Cell One Partners and Center for Breakthrough Medicines Announce Strategic Partnership to Accelerate Cell and Gene Therapy Commercialization

Center for Breakthrough Medicines, Nucleus Biologics, and Stoic Bio Announce Strategic Collaboration for Steady Supply of Quality Controlled Cell Culture Media to Expedite Development of Cell and Gene Therapies